These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

660 related items for PubMed ID: 10178650

  • 1. Pharmacoeconomic analysis of oral antifungal therapies used to treat dermatophyte onychomycosis of the toenails. A US analysis.
    Gupta AK.
    Pharmacoeconomics; 1998 Feb; 13(2):243-56. PubMed ID: 10178650
    [Abstract] [Full Text] [Related]

  • 2. Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States.
    Gupta AK.
    J Am Acad Dermatol; 2000 Oct; 43(4 Suppl):S81-95. PubMed ID: 11051137
    [Abstract] [Full Text] [Related]

  • 3. Treatment of dermatophyte toenail onychomycosis in the United States. A pharmacoeconomic analysis.
    Gupta AK.
    J Am Podiatr Med Assoc; 2002 May; 92(5):272-86. PubMed ID: 12015408
    [Abstract] [Full Text] [Related]

  • 4. Pharmacoeconomic analysis of oral therapies for onychomycosis: a US model.
    Marchetti A, Piech CT, McGhan WF, Neugut AI, Smith BT.
    Clin Ther; 1996 May; 18(4):757-77; discussion 702. PubMed ID: 8879902
    [Abstract] [Full Text] [Related]

  • 5. Economic evaluation of antifungal agents in the treatment of toenail onychomycosis in Germany.
    Van Doorslaer EK, Tormans G, Gupta AK, Van Rossem K, Eggleston A, Dubois DJ, De Doncker P, Haneke E.
    Dermatology; 1996 May; 193(3):239-44. PubMed ID: 8944348
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes.
    Gupta AK, Gregurek-Novak T.
    Dermatology; 2001 May; 202(3):235-8. PubMed ID: 11385230
    [Abstract] [Full Text] [Related]

  • 7. A cost/efficacy analysis of oral antifungals indicated for the treatment of onychomycosis: griseofulvin, itraconazole, and terbinafine.
    Angello JT, Voytovich RM, Jan SA.
    Am J Manag Care; 1997 Mar; 3(3):443-50. PubMed ID: 10173095
    [Abstract] [Full Text] [Related]

  • 8. Economic analysis of oral and topical therapies for onychomycosis of the toenails and fingernails.
    Casciano J, Amaya K, Doyle J, Arikian S, Shear N, Haspel M, Kahler K.
    Manag Care; 2003 Mar; 12(3):47-54. PubMed ID: 12685377
    [Abstract] [Full Text] [Related]

  • 9. Cost effectiveness of continuous terbinafine compared with intermittent itraconazole in the treatment of dermatophyte toenail onychomycosis: an analysis of based on results from the L.I.ON. study. Lamisil versus Itraconazole in Onychomycosis.
    Jansen R, Redekop WK, Rutten FF.
    Pharmacoeconomics; 2001 Mar; 19(4):401-10. PubMed ID: 11383756
    [Abstract] [Full Text] [Related]

  • 10. A multinational pharmacoeconomic analysis of oral therapies for onychomycosis. The Onychomycosis Study Group.
    Arikian SR, Einarson TR, Kobelt-Nguyen G, Schubert F.
    Br J Dermatol; 1994 Apr; 130 Suppl 43():35-44. PubMed ID: 8186141
    [Abstract] [Full Text] [Related]

  • 11. Terbinafine: a review of its use in onychomycosis in adults.
    Darkes MJ, Scott LJ, Goa KL.
    Am J Clin Dermatol; 2003 Apr; 4(1):39-65. PubMed ID: 12477372
    [Abstract] [Full Text] [Related]

  • 12. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis.
    Gupta AK, Ryder JE, Johnson AM.
    Br J Dermatol; 2004 Mar; 150(3):537-44. PubMed ID: 15030339
    [Abstract] [Full Text] [Related]

  • 13. Single-blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly.
    Gupta AK, Konnikov N, Lynde CW.
    J Am Acad Dermatol; 2001 Mar; 44(3):479-84. PubMed ID: 11209118
    [Abstract] [Full Text] [Related]

  • 14. A questionnaire study on the management of onychomycosis: a Canadian perspective.
    Gupta AK, Shear NH.
    Int J Dermatol; 1998 Jun; 37(6):457-60. PubMed ID: 9646138
    [Abstract] [Full Text] [Related]

  • 15. Oral antifungal medication for toenail onychomycosis.
    Kreijkamp-Kaspers S, Hawke K, Guo L, Kerin G, Bell-Syer SE, Magin P, Bell-Syer SV, van Driel ML.
    Cochrane Database Syst Rev; 2017 Jul 14; 7(7):CD010031. PubMed ID: 28707751
    [Abstract] [Full Text] [Related]

  • 16. Pharmacoeconomic analysis of the new oral antifungal agents used to treat toenail onychomycosis in the USA.
    Gupta AK, Lambert J.
    Int J Dermatol; 1999 Sep 14; 38 Suppl 2():53-64. PubMed ID: 10515529
    [No Abstract] [Full Text] [Related]

  • 17. A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis.
    Gupta AK, Shear NH.
    Drug Saf; 2000 Jan 14; 22(1):33-52. PubMed ID: 10647975
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of two new treatments for onychomycosis: an analysis of two comparative clinical trials.
    Bootman JL.
    J Am Acad Dermatol; 1998 May 14; 38(5 Pt 3):S69-72. PubMed ID: 9594941
    [Abstract] [Full Text] [Related]

  • 19. [Oral treatment of onychomycosis of the toe nails; comparison of cost-effectiveness of griseofulvin, itraconazole, ketoconazole and terbinafine].
    Bergman W, Rutten FF.
    Ned Tijdschr Geneeskd; 1994 Nov 19; 138(47):2346-50. PubMed ID: 7969635
    [Abstract] [Full Text] [Related]

  • 20. The new oral antifungal agents for onychomycosis of the toenails.
    Gupta AK, Shear NH.
    J Eur Acad Dermatol Venereol; 1999 Jul 19; 13(1):1-13. PubMed ID: 10565624
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.